Advarra finds new owner in Genstar Capital

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/pichet_w)
(Image: Getty/pichet_w)

Related tags: Genstar Capital, Private equity, advarra

Genstar Capital, the private equity firm behind CRF Bracket, is set to acquire Advarra from its current owners, Linden Capital Partners.

Headquartered in Columbia, MD, Advarra provides institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance services.

The company – formed in 2017 through the merger​ of Chesapeake IRB and Schulman IRB – has signed an agreement to be acquired by Genstar Capital. 

"Our partnership with Genstar will help Advarra continue to invest in our people and our technology, as well as support the evaluation and pursuit of future growth opportunities that will further enhance Advarra’s position,"​ Pat Donnelly, Advarra CEO, told us. 

"We were attracted to Genstar based on their strong history of supporting the growth and development of life sciences companies as well as a shared vision to enhance the safety and efficiency of clinical research," ​he said.

San Francisco, CA-based Genstar Capital also has invested in ERT, Catalent, and PRA Health Sciences, and last year formed CRF Bracket after purchasing CRF Health in July​ and combining the company with Bracket, which it acquired in 2017​. The PE firm currently has approximately $17bn of assets under management.

Advarra’s current owners, Linden Capital Partners, intend to reinvest in the company after the transaction completes, via a minority investment. Linden President and Managing Partner Tony David said in a statement that the IRB is “very well positioned to continue on its growth trajectory.” ​Advarra earlier this year​ acquired the central IRB, Qurorum, and its research and technology consulting division, Kinetiq.

David Golde, managing director of Genstar, said in a statement: “We are excited for Advarra to continue leveraging its leading reputation in the IRB and regulatory compliance industry, while expanding, both organically and through strategic acquisitions, into other ancillary services to better serve its customers.”

Related news

Show more

Related products

show more

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars